Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity Interactive Data Current Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] ASSETS Current assets: Cash and cash equivalents Receivable from collaboration partner Prepaid expenses and other current assets Deferred contract acquisition costs - current portion Total current assets [Assets, Current] Property and equipment, net Right of use asset - operating lease Deferred offering costs Deferred contract acquisition costs - non-current portion Security deposits and other assets Total assets [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Deferred revenue - current portion Operating lease obligation - current portion Financing lease obligation - current portion Total current liabilities [Liabilities, Current] Non-current liabilities: Accrued dividends on Series B Preferred Stock Deferred revenue - non-current portion Operating lease obligation - non-current portion Total non-current liabilities [Liabilities, Noncurrent] Total liabilities [Liabilities] Stockholders' equity: Preferred stock value Common stock, $0.001 par value; 325,000,000 shares authorized at June 30, 2021 and March 31, 2021; 191,632,008 and 180,751,234 shares issued at June 30, 2021 and March 31, 2021, respectively Additional paid-in capital Treasury stock, at cost, 135,665 shares of common stock held at June 30, 2021 and March 31, 2021 [Treasury Stock, Value] Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity [Liabilities and Equity] Preferred stock, par value Preferred stock, authorized Common stock, par value Common stock, authorized Common stock, issued Treasury stock, shares Preferred stock, issued Preferred stock, outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sublicense revenue Total revenues [Revenues] Operating expenses: Research and development General and administrative Total operating expenses [Operating Expenses] Loss from operations [Operating Income (Loss)] Other income (expenses), net: Interest income (expense), net Other income Loss before income taxes [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income taxes Net loss and comprehensive loss [Net Income (Loss) Attributable to Parent] Accrued dividends on Series B Preferred stock Net loss attributable to common stockholders Basic and diluted net loss attributable to common stockholders per common share Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share CONSOLIDATED STATEMENTS OF CASH FLOWS Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Expense related to write-off of deferred offering costs Changes in operating assets and liabilities: Receivable from collaboration partner [Increase (Decrease) in Other Receivables] Prepaid expenses and other current assets [Increase (Decrease) in Prepaid Expense and Other Assets] Right of use asset - operating lease [Operating Lease, Right-of-Use Asset, Amortization Expense] Operating lease liability Deferred sublicense revenue, net of deferred contract acquisition costs Accounts payable and accrued expenses Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from property and investing activities: Purchases of laboratory and other equipment [Payments to Acquire Property, Plant, and Equipment] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Cash flows from financing activities: Net proceeds from issuance of common stock and warrants, including option exercises Net proceeds from exercise of warrants Payments related to registration of shares underlying At the Market (ATM) facility and outstanding warrants [Payments of Merger Related Costs, Financing Activities] Net proceeds from sale of common stock under equity line Proceeds from issuance of note under Payroll Protection Plan Repayment of capital lease obligations [Repayments of Long-term Capital Lease Obligations] Repayment of notes payable [Repayments of Notes Payable] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of noncash activities: Insurance premiums settled by issuing note payable Accrued dividends on Series B Preferred CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statement Equity Components [Axis] Common Stock Series A Preferred Stock [Member] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Additional Paid-In Capital Treasury Stock Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount [Stockholders' Equity Attributable to Parent] Proceeds from sale of units of common stock and warrants for cash in private placement, shares for cash in private placement, amount Net proceeds from sale of common stock under equity line, shares Net proceeds from sale of common stock under equity line, amount Issuance of common stock at fair value for professional services, shares Issuance of common stock at fair value for professional services, amount Sale of common stock pursuant to 2019 Employee Stock Purchase Plan, shares Purchase Plan, amount Expenses related to S-3 registration statement for warrant shares [Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount] Accrued dividends on Series B Preferred stock [Accrued dividends on Series B Preferred stock] Stock-based compensation expense Net loss for the quarter ended June 30, 2020 Stock-based compensation expense (including ESPP) Proceeds from exercise of warrants, shares Proceeds from exercise of warrants, amount Conversion of Series D Preferred stock into common stock, shares Conversion of Series D Preferred stock into common stock, amount Issuance of common stock upon cashless exercise of options, shares Issuance of common stock upon cashless exercise of options, amount Issuance of common stock upon exercise of options for cash, shares Issuance of common stock upon exercise of options for cash, amount Balance, shares Balance, amount Description of Business Note 1 - Description of Business Note 2 - Basis of Presentation and Going Concern Summary of Significant Accounting Policies Note 3 - Summary of Significant Accounting Policies Receivable from Collaboration Partner Note 4 -Receivable from Collaboration Partner Prepaid Expenses and Other Current Assets Note 5 - Prepaid Expenses and Other Current Assets Property and Equipment Note 6 - Property and Equipment Accrued Expenses Note 7 - Accrued Expenses Capital Stock Note 8 - Capital Stock Related Party Transactions Note 9 - Related Party Transactions Commitments, Contingencies Note 10 - Commitments, Contingencies, Sublicensing and Collaborative Agreements Note 11 - Licensing, Sublicensing and Collaborative Agreements Subsequent Events Note 12 - Subsequent Events Use of Estimates Revenue Recognition Research and Development Expenses Stock-Based Compensation Right of Use Assets and Operating Lease Obligations Comprehensive Loss Loss per Common Share Fair Value Measurements Recent Accounting Pronouncements Schedule of basic and diluted net loss attributable to common stockholders per share Schedule of potentially dilutive securities excluded in determining diluted net loss per common share Schedule of Stock based compensation Schedule of acquisition costs Schedule of deferred revenue Schedule of prepaid expenses and other current assets Schedule of property and equipment Assets subject to financing lease Schedule of accrued expenses Schedule of outstanding warrants to purchase shares Summary of presentation of operating lease Summary of expected lease expense Supplemental disclosure of cash flow information Other lease disclosure Schedule of future minimum payments under operating leases Consolidated Entities [Axis] Plan Name [Axis] Related Party Transaction [Axis] Underwriting Agreement [Member] Market Sale Agreement [Member] Jefferies LLC [Member] Accumulated deficit Gross proceeds Exercise of outstanding warrants Net cash proceeds Series of convertible preferred stock Aggregate shares of common stock Aggregate shares of common stock, amount Purchase of warrants outstanding Additionally shares options granted Additionally shares options granted, amount Upfront license payment Acquisition description Cash and cash equivalents [Cash and cash equivalents] Pubclic offering price per share Series D of convertible preferred stock shares Warrants recieved Offering expenses Shares of common stock Aggregate offering price description Deferred Revenue Arrangement Type Axis Contract Liabilities Current Contract Liabilities Non-Current Contract liabilities: deferred revenue, beginning [Deferred Revenue] Additions Deductions [Deferred Revenue, Refund Payments] Contract liabilities: deferred revenue, ending Capitalized Contract Cost Axis Deferred Contract Acquisition Costs: Current Deferred Contract Acquisition Costs: Non Current Deferred contract acquisition costs, beginning [Deferred Costs] Additions [Deferred Policy Acquisition Cost, Capitalization] Deductions [Deferred Policy Acquisition Costs, Disposition] Deferred contract acquisition costs, ending Income Statement Location [Axis] Research and Development Expense General and Administrative Expense Stock option expense Range Axis 2019 Plan Minimum Maximum Market price per share at grant date Exercise price per share Risk-free interest rate Estimated term in years Volatility Dividend rate Shares portion Fair value per share Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis 2016 Equity Incentive Plan and 2019 Plan [Member] Warrant Antidilutive securities Business Combination, Separately Recognized Transactions [Axis] 2016 Equity Incentive Plan and 2019 Plan [Member] PH94B [Member] 2019 Employee Stock Purchase Plan [Plan] 2019 Plan 2019 Omnibus Equity Incentive Plan Employees Proceeds from non-refundable upfront license fee Revenue Weighted average exercise price Stock options outstanding Sublicense fees Unregistered common stock issued for acquisition Costs Unregistered common stock issued for acquisition Costs, value Acquisition Costs Amortization of contract acquisition costs Research and development expense General and administrative expense Option vested percentage Common stock shares reserved for future issuance Vesting percentages Clinical and nonclinical materials and contract services Insurance All other Prepaid expenses and other current assets Property, Plant and Equipment, Type [Axis] Constructions Information Technology Equipment Laboratory Equipment Tenant Improvements Manufacturing Equipment Office furniture and equipment Accumulated depreciation and amortization [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Property and equipment, gross Property and equipment, net Office equipment Accumulated depreciation [Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation] Net book value Accrued for clinical and nonclinical materials, development and contract services Accrued compensation Accrued professional services All other [Other Accrued Liabilities, Current] Accrued expenses Capital Stock (Details) Class Of Warrant Or Right Axis Warrant 1 Warrant 2 Warrant 3 Warrant 4 Warrant 5 Warrant 6 Warrant 7 Warrant 8 Warrants outstanding Warrants exercisable Average per share Expiration date range Award Type [Axis] Award Date [Axis] Purchase Agreement [Member] Lincoln Park Capital Fund [Member] December 2020 [Member] Open Market Sale Agreement [Member] May 2021 [Member] April 2021 Aggregate share purchase of common stock Proceeds from issuance of cash Exercise price Option to purchase shares of Commons shares Cash process received from stock option Aggregate shares issued of common stock shares ESPP purchase share of common stock Proceed recieved under ESPP Warrants outstanding purchase shares Weighted average exercise price [Weighted average exercise price] Wannrats exercise price Warrants description Unregistered shares of common stock sold Common Stock Purchase Agreement, Description Price per share Issuence of unregistered shares of common stock Fair value of the Commitment Shares Registered shares of common stock sold Aggregate gross cash proceeds Proceeds from cash received Series D Preferred stock, outstanding Conversion of convertible common stock Preferred stock shares issued Intial offering price aggregate amount Commission percent upon sales Conversion of Series D Preferred stock into common stock Depreciation and amortization Accounts payable and accrued liabilities Research and devlopment expense Right of use asset - operating lease [Right of use asset - operating lease] Current operating lease obligation Non-current operating lease obligation Total operating lease liability 2022 2023 2024 2025 2026 Thereafter Total lease expense Less imputed interest [Lessee, Operating Lease, Liability, Undiscounted Excess Amount] Present value of operating lease liabilities Assumed remaining lease term in years Assumed discount rate Cash paid for amounts included in the measurement of lease liabilities Operating lease cost current Facility rent expense Sublicensing and Collaborative Agreements (Details Narrative) AffaMed Agreement [Member] Performance obligations Upfront license payment Devlopment and commercelization Revenue 2019 [Member] Exercise of warrants, shares Exercise of warrants, amount Purchase of options Carrying value as of the balance sheet date of obligations incurred through that date and payable for development expenses. Refers to amount of accrued dividend on preferred stock during the period. Gross number of share options (or share units) granted during the period. Carrying value of security deposits and other assets as on balance sheet date. Refers to amount of non current portion of accrued dividend as on balance sheet date. Refers to amount of non cash expense insurance premium settled issuing notes payable during the period. Refers to accrued dividend on series B preferred stock. Refers to accrued dividend on series B preferred stock. Disclosure regarding of prepaid and other assets. Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readil Amount of lessee's right to use underlying asset under operating lease. Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. Percentage of vesting of award under share-based payment arrangement. The cash inflow from the additional capital contribution to the entity. General description of liabilities to third parties under a termination loan agreement, whether or not guaranteed by the government, including a cross reference to the related termination claim or claims recorded or disclosed at the latest balance sheet d Amount of revenue earned by the entity based on the investment results achieved. Excludes fees based upon a percentage of the assets under management not performance-related.